MedTrace Logo

Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography

NCT03490916 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-05-10

Study results available
· View outcomes & findings →

Summary

The overall goal of this study is to detect preclinical signs of HAPE by lung ultrasonography and evaluate the effectiveness of acetazolamide at decreasing pulmonary edema by using ultrasound.

Conditions

  • High Altitude Pulmonary Edema

Interventions

DRUG

Acetazolamide

Administration of Acetazolamide

DRUG

Placebo

Administration of Placebo

Sponsors & Collaborators

  • Vincent Kan

    lead OTHER

Principal Investigators

  • Hillary Irons, MD, PhD · University of Massachusetts, Worcester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-23
Primary Completion
2018-04-04
Completion
2018-04-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03490916 on ClinicalTrials.gov